BRINSUPRI Approval Tests Rare Disease Supply Chain Readiness

Insmed's BRINSUPRI (brensocatib) cleared FDA approval on August 12, 2025, as the first DPP1 inhibitor indicated for non-cystic fibrosis bronchiectasis in adults and adolescents aged 12 and older. For manufacturing and regulatory operations teams, the approval of a first-in-class oral solid dosage form for a chronic, progressive rare disease signals immediate pressure on process validation strategies and global distribution infrastructure built to sustain long-term, once-daily patient regimens.

The clinical package supporting approval comprised two randomized, placebo-controlled trials, ASPEN and WILLOW, enrolling a combined 1,977 patients across 38 countries and 503 investigational centers. ASPEN ran 52 weeks and enrolled 1,680 adults and 41 adolescents; WILLOW ran 24 weeks and enrolled 256 adults. Both trials evaluated 10 mg and 25 mg oral tablet doses administered once daily. The primary efficacy endpoint in both trials was reduction in pulmonary exacerbations, defined as worsening of three or more major symptoms over 48 hours requiring antibiotic treatment. Of the 1,977 enrolled patients, 1,974 were evaluable for safety, and 309 were from the United States.

The breadth of the trial geography, spanning sites from Malaysia and Taiwan to Peru and Serbia, reflects the global patient population Insmed must now supply under commercial GMP conditions. For QA and regulatory affairs leads, the transition from clinical to commercial manufacturing for a novel mechanism-of-action compound requires documented process validation under 21 CFR Part 211 and ICH Q10 quality system expectations, with particular attention to ensuring sterility assurance and dosage uniformity across both the 10 mg and 25 mg strengths at commercial scale.

NCFB is a chronic and progressive inflammatory lung condition causing recurrent pulmonary exacerbations that cumulatively damage airway architecture. As the disease progresses, patients require long-term antibiotics, oxygen, physiotherapy, and mucolytics. A once-daily oral tablet approved for patients as young as 12 introduces pediatric formulation and labeling considerations that supply chain planners and regulatory teams will need to address across markets where ex-US submissions are anticipated. Source: FDA Drug Trials Snapshots: BRINSUPRI, published April 28, 2026, fda.gov.